Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 11/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31240748 | 1.00 | LPL (0.49) | LPLLIPGCA12CA1CA9 | |
| SCHEMBL28628663 | 0.86 | LPL (0.44) | LPLLIPGCA12CA1CA9 | |
| SCHEMBL16426120 | 0.86 | LPL (0.44) | LPLLIPGCA12CA1CA9 | |
| SCHEMBL9948194 | 0.86 | LPL (0.57) | LPLLIPGCA12CA1CA9 | |
| SCHEMBL14748338 | 0.79 | LPL (0.50) | LPLLIPGCA12CA1CA9 | |
| SCHEMBL14509140 | 0.79 | ALDH1A1 (0.44) | LPLLIPGCA1CA9HCAR1 | |
| SCHEMBL4244671 | 0.78 | LPL (0.38) | LPLLIPGCA1CA9HCAR1 | |
| SCHEMBL7887164 | 0.78 | LPL (0.49) | LPLLIPGCA12CA1CA9 | |
| SCHEMBL29925307 | 0.78 | LPL (0.38) | LPLLIPGCA1CA9HCAR1 | |
| SCHEMBL30236796 | 0.78 | LPL (0.49) | LPLLIPGCA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023016527-A1 | CLASS OF BENZOXAZINE SPIRO COMPOUNDS AND PREPARATION METHOD THEREFOR | 南京明德新药研发有限公司 | 2023-02-16 | — | — | WO | disclosed |
| EP-3191454-B1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-10-24 | — | — | EP | disclosed |
| US-9938222-B2 | Cyclopropanecarboxylic acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170253554-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-07 | — | — | US | disclosed |
| EP-3191454-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2970293-B1 | 2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL)METHYL)-3-(2-(TRIFLUOROMETHYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | RESPIVERT LTD (GB) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016040222-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253554-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | GPR88, GPBAR1, GPR68 | LPL 3245/4885LIPG 2490/4885CA12 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.